NCT07094880View on ClinicalTrials.gov

Subcuteous Methotrexate in Rheumatoid Arthritis

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 1, 2015

Primary Completion Date

June 1, 2016

Study Completion Date

June 1, 2016

Conditions
Methotrexate Adverse ReactionAdvantage of Using Subcutaneous Route for Methotrexate
Interventions
DRUG

Tab. Methotrexate 25mg/week

Tab. Methotrexate will be given orally in one arm at a dose of 25 mg/week

DRUG

Inj. Methotrexate 25mg/week

Inj. Methotrexate 25 mg/week will be given subcutaneously in another arm

All Listed Sponsors
lead

Bangladesh Medical University

OTHER

NCT07094880 - Subcuteous Methotrexate in Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter